News

Company’s decision to lengthen lipid lowering trial causes controversy

BMJ 2008; 336 doi: 10.1136/bmj.39545.529028.DB (Published 10 April 2008)
Cite this as: BMJ 2008;336:797.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeanne Lenzer

    The decision to extend enrolment of participants in a lipid lowering trial that was set to come to an end in 2011 because the target for enrolments had already been exceeded is causing controversy.

    The delay follows an earlier row about the delayed reporting of the results of another study of the same drug, ezetimibe, which is manufactured jointly by Merck and Schering-Plough and sold singly as Ezetrol in the United Kingdom and as Zetia in the United States, or in combination with simvastatin as Inegy in the UK and Vytorin in the US (BMJ 2008;336:180-1; doi: 10.1136/bmj.39468.610775.DB).

    Merck and Schering-Plough published a news release on 28 March stating that they will extend enrolment …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular